Literature DB >> 17227202

Practice patterns for managing Helicobacter pylori infection and upper gastrointestinal symptoms.

Colin W Howden1, Steven W Blume, Gregory de Lissovoy.   

Abstract

OBJECTIVE: To assess adherence with guidelines for testing and treatment of Helicobacter pylori infection and upper gastrointestinal symptoms. STUDY
DESIGN: Retrospective longitudinal cohort analysis of patient-level medical and pharmacy claims from 75 US managed care plans.
METHODS: Persons with new claims for antisecretory medication, H pylori tests, or endoscopies were selected from among 2 million plan members continuously enrolled from 2001 to 2004 and were grouped by initial clinical diagnosis (3456 with peptic ulcer disease [PUD], 14,593 with nonulcer dyspepsia [NUD], and 36,233 with gastroesophageal reflux disease [GERD]). Diagnostic procedures, medications received, and sequencing of specific procedures and medications were examined relative to published guidelines by initial diagnosis, age, and physician specialty.
RESULTS: While guidelines recommend testing before treatment, one third of persons receiving antibiotics for H pylori infection had not first been tested for the infection. In one third of all posttreatment testing, primary care practitioners incorrectly used serologic tests, despite their inability to distinguish cured from active infection. Eighteen percent of patients with GERD were tested for H pylori, although there is no causal link between them. Only two thirds of patients aged 50 to 64 years with presumed PUD underwent endoscopy, which guidelines recommend for older adults; yet one third of patients with PUD aged 18 to 49 years, for whom prompt endoscopy is generally not recommended, had an endoscopy within 30 days of their index date.
CONCLUSIONS: Substantial noncompliance with widely disseminated guidelines calls for better understanding of appropriate indications for H pylori testing and endoscopy to improve patient care and conserve healthcare resources.

Entities:  

Mesh:

Year:  2007        PMID: 17227202

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  8 in total

1.  Improving compliance with helicobacter pylori eradication therapy: when and how?

Authors:  John P Anthony O'Connor; Ikue Taneike; Colm O'Morain
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

2.  The Urea Breath Test for the Noninvasive Detection of Helicobacter pylori.

Authors:  Anthony O'Connor
Journal:  Methods Mol Biol       Date:  2021

Review 3.  Update on the Management of Helicobacter pylori Infection.

Authors:  Nasir Saleem; Colin W Howden
Journal:  Curr Treat Options Gastroenterol       Date:  2020-07-17

4.  Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States.

Authors:  Hashem B El-Serag; John Y Kao; Fasiha Kanwal; Mark Gilger; Frank LoVecchio; Steven F Moss; Sheila E Crowe; Adam Elfant; Thomas Haas; Ronald J Hapke; David Y Graham
Journal:  Clin Gastroenterol Hepatol       Date:  2018-03-17       Impact factor: 11.382

5.  Adherence to best practice guidelines in dyspepsia: a survey comparing dyspepsia experts, community gastroenterologists and primary-care providers.

Authors:  B M R Spiegel; M Farid; M G H van Oijen; L Laine; C W Howden; E Esrailian
Journal:  Aliment Pharmacol Ther       Date:  2009-01-15       Impact factor: 8.171

6.  Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole.

Authors:  Robert C Heading; Hubert Mönnikes; Anne Tholen; Holger Schmitt
Journal:  BMC Gastroenterol       Date:  2011-05-11       Impact factor: 3.067

7.  The epidemiology, diagnosis, and cost of dyspepsia and Helicobacter pylori gastritis: a case-control analysis in the Southwestern United States.

Authors:  Douglas Mapel; Melissa Roberts; Andrew Overhiser; Andrew Mason
Journal:  Helicobacter       Date:  2012-09-04       Impact factor: 5.753

8.  Factors influencing treatment outcome in patients with gastroesophageal reflux disease: outcome of a prospective pragmatic trial in Asian patients.

Authors:  Khean Lee Goh; Kee Don Choi; Myung-Gyu Choi; Tsai-Yuan Hsieh; Hwoon-Yong Jung; Han-Chung Lien; Jayaram Menon; Steven Mesenas; Hyojin Park; Bor-Shyang Sheu; Justin Cy Wu
Journal:  BMC Gastroenterol       Date:  2014-09-09       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.